Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

By J. Neoptolemos, D. Palmer, P. Ghaneh, E. Psarelli, J. Valle, C. Halloran, O. Faluyi, D. O’reilly, D. Cunningham, J. Wadsley and 24 more. The Lancet, 2017

1,690 citations recorded by the source corpus.

Subfields: Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/fb5832f1e962d4fc60f0cb854aa21b22a7f7a790